Summary
Alnylam Pharmaceuticals, Inc. (ALNY) reported its financial results for the quarterly period ended June 30, 2010. As a clinical-stage biopharmaceutical company, Alnylam's financial performance is characterized by significant research and development expenses, offset by collaboration revenues. The company continued to advance its pipeline of RNAi therapeutics, a novel approach to treating diseases. Investors should note the ongoing investment in R&D as a key indicator of future potential, alongside the company's cash burn rate and its ability to fund its operations through existing cash and potential future financing or partnerships.
Financial Highlights
41 data pointsBeta
Financial Statements
Beta
| Revenue | $26.62M |
| R&D Expenses | $28.14M |
| Operating Expenses | $38.24M |
| Operating Income | -$11.63M |
| Net Income | -$14.63M |
| EPS (Basic) | $-0.35 |
Key Highlights
- 1Alnylam Pharmaceuticals is a clinical-stage biopharmaceutical company focused on RNAi therapeutics.
- 2The company incurred net losses, typical for its stage of development, driven by substantial R&D expenditures.
- 3Collaboration and licensing revenues contributed to offsetting operating expenses.
- 4The company's balance sheet shows a significant cash and cash equivalents position, indicating a runway for operations.
- 5Alnylam's risk factors section highlights the inherent uncertainties in drug development, regulatory approvals, and market competition.
- 6The filing indicates that Alnylam is a large accelerated filer, suggesting a certain level of financial maturity and reporting history.
Frequently Asked Questions
Alnylam Pharmaceuticals is focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. These are novel medicines designed to treat a wide range of debilitating diseases.
As a clinical-stage company, Alnylam incurs significant R&D expenses and typically generates net losses. Funding is primarily provided through its existing cash reserves, and potentially through strategic collaborations, licensing agreements, and equity financings.
The primary risks for Alnylam, as detailed in its risk factors, include the inherent uncertainties in the development and regulatory approval process for new drugs, potential competition from other therapeutic approaches, reliance on strategic partnerships, and the ability to successfully commercialize its products if approved.